<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02136004</url>
  </required_header>
  <id_info>
    <org_study_id>REX-US-2027-001</org_study_id>
    <nct_id>NCT02136004</nct_id>
  </id_info>
  <brief_title>The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System</brief_title>
  <acronym>Closer</acronym>
  <official_title>The Closer Trial: A Multi-center, Prospective, Single Arm Trial to Evaluate the Safety and Efficacy of the Rex Medical Closer Vascular Sealing System (VSS) for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to demonstrate the safety and effectiveness of the Rex Medical
      Closer Vascular Sealing System in sealing femoral arterial access sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the trial is to demonstrate the safety and effectiveness of the Rex Medical
      Closer Vascular Sealing System (VSS) in sealing femoral arterial access sites and providing
      reduced times to hemostasis (TTH) compared with performance goals at the completion of
      diagnostic or interventional procedures performed through 5, 6 or 7 Fr procedural sheaths.
      This study will be considered a success (from a statistical perspective) if it meets both the
      Closer VSS superiority goal for the primary effectiveness analysis and the Closer VSS
      performance goal for the primary safety analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>procedural, usually within 15 minutes of enrollment</time_frame>
    <description>Primary effectiveness endpoint - elapsed time between the Closer VSS delivery system removal and first observed and confirmed arterial hemostasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Combined Major Access Site Closure-related Complications</measure>
    <time_frame>Through 30 days +/- 7 days</time_frame>
    <description>Primary safety endpoint - rate of combined major access site closure-related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>prior to hospital discharge, usually within 24 hours</time_frame>
    <description>Secondary efficacy endpoint - elapsed time between the Closer VSS delivery system removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding from the access site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge Eligibility</measure>
    <time_frame>prior to hospital discharge, usually within 24 hours</time_frame>
    <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject's access site is assessed to be hemodynamically stable, as determined by the investigator or his/her designee(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>through hospital discharge, usually within 24 hours</time_frame>
    <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject is actually physically discharged from the hospital ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>procedural, usually within 15 minutes of enrollment</time_frame>
    <description>Secondary efficacy endpoint - the ability to deploy the system, deliver the implant, and achieve arterial hemostasis with the Closer VSS alone or with post-hemostasis adjunctive compression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Combined Minor Access Site Closure-related Complications</measure>
    <time_frame>through 30 +/- 7 days</time_frame>
    <description>Secondary safety endpoint - rate of combined minor access site closure-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>through 30 days +/- 7 days</time_frame>
    <description>Secondary efficacy endpoint - attainment of final arterial hemostasis using any method and freedom from major access site closure-related complications through 30 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Surgical Wound</condition>
  <arm_group>
    <arm_group_label>Closer VSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closer VSS</intervention_name>
    <description>At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
    <arm_group_label>Closer VSS</arm_group_label>
    <other_name>Rex Medical Closer TM Vascular Sealing System (VSS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pre-Op Inclusion Criteria:

        1 - Acceptable candidates for an elective, non-emergent diagnostic or interventional
        endovascular procedure via the common femoral artery using a 5, 6, or 7 Fr introducer
        sheath.

        Exclusion Criteria:

        Pre-Operative Exclusion Criteria:

          1. - Significant bleeding diatheses or coagulopathy

          2. - Planned endovascular or surgical procedures within next 30 days

          3. - Planned ipsilateral femoral arteriotomy within next 90 days

          4. - Arteriotomy in ipsilateral groin within the past 30 days with any residual hematoma,
             significant bruising or vascular complication

          5. - Previous vessel closure device used in ipsilateral groin within the past 90 days

          6. - Previous vascular surgery or repair in the vicinity of the target access site

          7. - Severe peripheral vascular disease in the ipsilateral limb requiring surgical or
             endovascular treatment within the pervious 30 days or next 30 days

          8. - Existing nerve damage in ipsilateral limb

          9. - Extreme morbid obesity (BMI &gt; 4 kg/m2)

             Intra-operative Exclusion Criteria:

         10. - Use of a procedural sheath that is &lt; 5 Fr or &gt; 7 Fr

         11. - Difficult insertion of procedural sheath or needle stick problems at the onset of
             the procedure

         12. - Placement of an ipsilateral venous sheath for procedure

         13. - Procedural sheath placement either through the superficial femoral artery and into
             the profunda femoris artery, or placement at or distal to bifurcation of the
             superficial femoral artery and the profunda femoris artery

         14. - In subjects receiving unfractionated heparin, an ACT &gt; 350 seconds, or &gt; 250 seconds
             in the presence of a GP IIb/IIIa inhibitor

         15. - Procedures or existing medical conditions that may extend index hospitalization
             beyond 24 hours post-procedure

         16. - Systemic hypertension (SBP &gt; 180 mmHg) or hypotension (SBP &lt; 90 mmHg) just prior to
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shing-Chiu Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lafayette General Medical Center/Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Ohio Research</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Health Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Health Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>November 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arteriotomy</keyword>
  <keyword>vessel closure</keyword>
  <keyword>femoral access site</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After multi-center manuscript is published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Closer VSS</title>
          <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220">Enrollment commenced on May 20, 2014 and the last subject completed follow-up on February 28, 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Closer VSS - Diagnostic Cohort</title>
          <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomies in diagnostic endovascular cases.
Closer VSS: At the end of a percutaneous diagnostic endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
        </group>
        <group group_id="B2">
          <title>Closer VSS - Interventional Cohort</title>
          <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomies in interventional endovascular cases.
Closer VSS: At the end of a percutaneous interventional endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="10.3"/>
                    <measurement group_id="B2" value="64.7" spread="8.7"/>
                    <measurement group_id="B3" value="63.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis</title>
        <description>Primary effectiveness endpoint - elapsed time between the Closer VSS delivery system removal and first observed and confirmed arterial hemostasis</description>
        <time_frame>procedural, usually within 15 minutes of enrollment</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis</title>
          <description>Primary effectiveness endpoint - elapsed time between the Closer VSS delivery system removal and first observed and confirmed arterial hemostasis</description>
          <population>All subjects enrolled</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" lower_limit="0.74" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Combined Major Access Site Closure-related Complications</title>
        <description>Primary safety endpoint - rate of combined major access site closure-related complications</description>
        <time_frame>Through 30 days +/- 7 days</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Combined Major Access Site Closure-related Complications</title>
          <description>Primary safety endpoint - rate of combined major access site closure-related complications</description>
          <population>All subjects enrolled</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation</title>
        <description>Secondary efficacy endpoint - elapsed time between the Closer VSS delivery system removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding from the access site</description>
        <time_frame>prior to hospital discharge, usually within 24 hours</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation</title>
          <description>Secondary efficacy endpoint - elapsed time between the Closer VSS delivery system removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding from the access site</description>
          <population>All subjects enrolled</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="2.36" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge Eligibility</title>
        <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject's access site is assessed to be hemodynamically stable, as determined by the investigator or his/her designee(s)</description>
        <time_frame>prior to hospital discharge, usually within 24 hours</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge Eligibility</title>
          <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject's access site is assessed to be hemodynamically stable, as determined by the investigator or his/her designee(s)</description>
          <population>All subjects enrolled</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.62" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge</title>
        <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject is actually physically discharged from the hospital ward</description>
        <time_frame>through hospital discharge, usually within 24 hours</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge</title>
          <description>Secondary efficacy endpoint - elapsed time between Closer VSS delivery system removal and when subject is actually physically discharged from the hospital ward</description>
          <population>All subjects enrolled</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.12" lower_limit="10.93" upper_limit="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Secondary efficacy endpoint - the ability to deploy the system, deliver the implant, and achieve arterial hemostasis with the Closer VSS alone or with post-hemostasis adjunctive compression</description>
        <time_frame>procedural, usually within 15 minutes of enrollment</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Secondary efficacy endpoint - the ability to deploy the system, deliver the implant, and achieve arterial hemostasis with the Closer VSS alone or with post-hemostasis adjunctive compression</description>
          <population>All subjects enrolled</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Combined Minor Access Site Closure-related Complications</title>
        <description>Secondary safety endpoint - rate of combined minor access site closure-related complications</description>
        <time_frame>through 30 +/- 7 days</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Combined Minor Access Site Closure-related Complications</title>
          <description>Secondary safety endpoint - rate of combined minor access site closure-related complications</description>
          <population>All subjects enrolled</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>Secondary efficacy endpoint - attainment of final arterial hemostasis using any method and freedom from major access site closure-related complications through 30 days</description>
        <time_frame>through 30 days +/- 7 days</time_frame>
        <population>All subjects enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Closer VSS</title>
            <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success</title>
          <description>Secondary efficacy endpoint - attainment of final arterial hemostasis using any method and freedom from major access site closure-related complications through 30 days</description>
          <population>All subjects enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Closer VSS</title>
          <description>Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
Closer VSS: At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Serious device-related adverse events, excluding endpoint events</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious access site bleeding</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>S. Chiu Wong, MD</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>212-746-4644</phone>
      <email>scwong@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

